Key result
Continuous subcutaneous treprostinil infusion did not alter the pharmacodynamics or pharmacokinetics of warfarin, with 90% CIs for parameter ratios falling within the 0.80-1.25 no-effect range.
Why the study?
Does continuous subcutaneous treprostinil alter the pharmacodynamics and pharmacokinetics of warfarin?
RCT
Single-blind
Does continuous subcutaneous treprostinil alter the pharmacodynamics and pharmacokinetics of warfarin?
Absolute Event Rate: 219.58% vs 218.93%
Continuous subcutaneous treprostinil does not significantly affect the pharmacokinetics or pharmacodynamics of warfarin, indicating a low likelihood of clinically important drug interactions.
No takes yet. Share an insight, caveat, or question.
Supports concurrent use without warfarin adjustment; leaves open confirmation in larger PAH cohorts.
Wade et al. (2003) conducted an RCT in Pulmonary arterial hypertension. Continuous subcutaneous treprostinil vs. Vehicle was evaluated on Area under the effect-time curve (AUEC(0-1)) for warfarin INR (95% CI 0.80-1.25). Continuous subcutaneous treprostinil infusion did not alter the pharmacodynamics or pharmacokinetics of warfarin, with 90% CIs for parameter ratios falling within the 0.80-1.25 no-effect range.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: